Scott Dreyer Sells 49,976 Shares of Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Scott Dreyer sold 49,976 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president directly owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Scott Dreyer also recently made the following trade(s):

• On Monday, December 8th, Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00.

Collegium Pharmaceutical Stock Down 5.9%

Shares of COLL stock traded down $2.33 on Thursday, reaching $37.28. 902,832 shares of the stock were exchanged, compared to its average volume of 453,803. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 21.80 and a beta of 0.67. The business’s 50 day moving average price is $45.98 and its 200 day moving average price is $42.12. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The business had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. During the same period last year, the company earned $1.77 earnings per share. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. As a group, sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of several recent analyst reports. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Needham & Company LLC reduced their target price on Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of COLL. Rubric Capital Management LP raised its position in shares of Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Collegium Pharmaceutical by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Collegium Pharmaceutical by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock valued at $74,883,000 after acquiring an additional 18,160 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after acquiring an additional 538,337 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 0.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after acquiring an additional 3,891 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.